Drug class
Cytidine-5-diphosphocholine (CDP-choline); phospholipid precursor and neuroactive nutrient
Mechanism of action
An intermediate in the Kennedy pathway for phosphatidylcholine synthesis. After administration it is metabolised to choline and cytidine/uridine, which enter phospholipid and nucleotide pools; proposed neuroprotective effects are not established as a single proven clinical mechanism.
General use cases
- No broad FDA- or EMA-authorised therapeutic indication as a standalone medicine. It has been studied or marketed in some countries for stroke, cognitive impairment and neurological recovery, but such uses should be identified as jurisdiction-specific or investigational unless an applicable product label confirms them.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
